| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Arun Sanyal | 6 - 7:30 p.m. | Hall A, General Session | Presenter | Distinguished Awards and Awards and Honors Ceremony |
| Saul Karpen | 10:15 a.m. | Convention Center Upper Floor Room 1A and 1B | Panel Presenter | Liver Leaders Council Summit: How to Educate Physicians and APPs on Rare Disease |
| J.P. Arab | 8 - 9:30 a.m. | Ballroom 6C | Moderator | AASLD/ILTS Course, Part 1: Expanding the Donor Pool |
| M. Shadab Siddiqui | 8 - 9:30 a.m. | Hall A, General Session | Moderator | Post-Graduate Course, Parts 1-4: The Future is Here – Practicing Hepatology in 2024 (ticketed event) |
| Yaping Wang | 8 a.m. - 5 p.m. | Hall C, 1075 | Abstract Poster | Potential of Novel Regulatory Bile Acid, 3β-Sulfate-5-Cholestenoic Acid (3SCA) in MASLD Therapy |
| M. Shadab Siddiqui | 8 a.m. - 5 p.m. | Hall C, 1539 | Abstract Poster | Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients |
| Kevin Houston | 8 a.m. - 5 p.m. | Hall C, 1612 | Abstract Poster | Designation of Acute-on-chronic Liver Failure in Patients with Severe Alcoholic Hepatitis |
School of Medicine
The Liver Meeting 2024
A delegation from the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, led by Institute Director Arun Sanyal, M.D., FAASLD, and Chief Scientific Officer Saul Karpen, M.D., Ph.D., FAASLD, incoming president-elect of AASLD, will be attending The Liver Meeting 2024, in San Diego.
In addition to seeing our keynote presentations, moderated sessions and abstract posters, we invite you to come visit us in Booth 1152, near the TLM Theater 2 in Exhibit Hall BC.
VCU @ TLM day by day
To see the full list of VCU's presence at The Liver Meeting 2024, select a date below:
Friday, Nov. 15
Saturday, Nov. 16
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Arun Sanyal | 2:45 - 3 p.m. | Ballroom 6B | Presenter | Future Directions and Unmet Needs in Steatotic Liver Disease |
| J.P. Arab | 2:30 - 2:45 p.m. | Ballroom 6B | Presenter | MetALD: Clinical Trial Design and Drug Development |
| J.P. Arab | 8 - 9:30 a.m. | Ballroom 6B | Moderator | Metabolic Dysfunction-associated Steatotic Liver Disease, Alcohol-associated Liver Disease, and MetALD: Beyond the Nomenclature, Part 1 |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 2520 | Abstract Poster | Serum and Urinary Metabolomics are Associated with the Development of De Novo Metabolic Syndrome after Liver Transplant: A Multi-center Longitudinal study |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 2264 | Abstract Poster | Salivary Microbiome is Independently Associated with Hospitalizations in a Multi-center Prospective Cohort of Outpatients with Cirrhosis: NACSELD3 Experience |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 2158 | Abstract Poster | Disparities and Barriers in Improving Oral Health in Cirrhosis: The ORACLE (Oral Health in Cirrhosis of the Liver) Study |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 2155 | Abstract Poster | Hospitalized Patients with Cirrhosis, Especially Those Not in High Income Countries Continue to Have Worse Outcomes Regardless of Whether Outcomes were Studies During and After COVID |
| Alana Saddic | 8 a.m. - 5 p.m. | Hall C, 2149 | Abstract Poster | Health Literacy and Education Level Are Determinants of Disease Severity in Metabolic Dysfunction Associated Steatotic Liver Disease |
| Jing Zeng | 8 a.m. - 5 p.m. | Hall C, 2111 | Abstract Poster | Identification of Novel Circulating Exosomal miRNAs and mRNA Networks Contributing to the Progression from MASH to HCC |
| Jing Zeng | 8 a.m. - 5 p.m. | Hall C, 2254 | Abstract Poster | Duodenal Mitochondrial Oxidative Phosphorylation Worsens with Disease Progression and is Ameliorated After FMT in Patients with Cirrhosis |
| Amon Asgharpour | 8 a.m. - 5 p.m. | Hall C, 2024 | Abstract Poster | Automated Digital Analysis of SHH–injured Area Correlates with Conventional and Digital Pathologies in MASLD and MASH patients |
| Amon Asgharpour | 8 a.m. - 5 p.m. | Hall C, 2025 | Abstract Poster | Validation of the Diagnostic Enrichment Utility of NIS2+® for Varying Phenotypes of Metabolic Dysfunction Associated Steatotic Liver Disease |
| Amon Asgharpour | 8 a.m. - 5 p.m. | Hall C, 2026 | Abstract Poster | Performance Metrics of Spleen Stiffness Measurement (SSM) Obtained by Transient Elastography in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) |
| Arun Sanyal | 8 a.m. - 5 p.m. | Hall C, 2117 | Abstract Poster | The ELF Test Improves Risk Stratification Versus Histological Staging for Prediction of Clinical and Histological Outcomes in MASH and Advanced Fibrosis |
| Arun Sanyal | 8 a.m. - 5 p.m. | Hall C, 2117 | Abstract Poster | The Diabetes Risk Index (DRI) Predicts Future Development of Type 2 Diabetes Mellitus in Euglycemic and Prediabetic Patients with Metabolic Dysfunction Associated Steatotic Liver Disease |
Sunday, Nov. 17
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| M. Shadab Siddiqui | 8 - 9:30 a.m. | Ballroom 6A | Presenter | MASLD and MASH – Natural History and Existing Therapy |
| Jasmohan Bajaj | 8:35 - 8:45 a.m. | Room 11 | Presenter | Navigating the Challenges: Understanding and Managing Complications of Cirrhosis or Living with Cirrhosis: Understanding and Coping with its complications |
| Jasmohan Bajaj | 8:35 - 8:45 a.m. | Room 11 | Presenter | Focus on Hepatic Encephalopathy |
| J.P. Arab | 5:20 - 5:40 p.m. | Room 11 | Presenter | Designing Clinical Trials for Alcohol-associated Liver Disease |
| R. Todd Stravitz | 11 a.m. - 12:30 p.m. | Room 28 A-D | Moderator | Acute Liver Failure: Pathophysiology, Prognostication, and Management |
| Gowthami Kanagalingam | 5:15 - 5:30 p.m. | Ballroom 6A | Abstract Parallel | Validation of the MASEF Score for Its Diagnostic Enrichment Utility for At-Risk MASH in the NIMBLE Project |
| Jawaid Shaw | 6:15 - 6:30 p.m. | Ballroom 6A | Abstract Parallel | HEROIC Trial: A Multi-Center Randomized Clinical Trial Using IT |
| Joy Lu | 8 a.m. - 5 p.m. | Hall C, 2520 | Abstract Poster | The Association of Dysregulated Sphingolipid Metabolism and microRNAs with Alcohol-associated Liver Diseases |
| Vinay Jahagirdar | 8 a.m. - 5 p.m. | Hall C, 3105 | Abstract Poster | Alcohol-associated Liver Diseases: Clinical and Experimental |
| Michael Eisworth | 8 a.m. - 5 p.m. | Hall C, 3568 | Abstract Poster | The Impact of IQR/Median on the Accuracy of Liver Stiffness Measurement Predicting Advanced Fibrosis on Liver Biopsy |
| Vinay Jahagirdar | 3 - 3:15 p.m. | Hall C, 3105 | Abstract Poster | Initiation of Naltrexone is Associated with Lower Rates of AKI, SBP, and Mortality in Patients with Decompensated Alcohol-associated Cirrhosis and Ascites |
| Arun Sanyal | 8 a.m. - 5 p.m. | Hall C, 3202 | Abstract Poster | Fibrosis Regression after Tirzepatide Treatment of Non-cirrhotic MASH for 52 Weeks Occurred in a Zone-Dependent Manner |
Monday, Nov. 18
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| Jasmohan Bajaj | 8 - 8:30 a.m. | Hall A – General Session | State of the Art Lecture | Leon Schiff Lecture: Hepatic Encephalopathy |
| Jasmohan Bajaj | 10 - 10:15 a.m. | Ballroom 6D | Presenter | Future-Proofing Your Research Portfolio – Diversifying Your Research Portfolio |
| Jasmohan Bajaj | 10 - 10:15 a.m. | Ballroom 6D | Presenter | Ultradeep Sequencing of the Gut Microbiome Shows Progressive Weaponization of Enterobacteriaceae with Cirrhosis Progression through Mobile Genetic Elements Which May Not Recover after FMT |
| Saul Karpen | 11:30 a.m. - 12:30 p.m. | Hall A – General Session | Moderator | Basic Science Plenary |
| Richard Sterling | 9:45 - 10:45 a.m. | Ballroom 6D | Moderator | Future-Proofing Your Research Portfolio |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 4067 | Abstract Poster | Proteomic and Metabolomic Analysis from the CONFIRM Trial Shows Biomarkers that Predict HRS Reversal without Vasoconstrictor Therapy |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 4198 | Abstract Poster | Rifaximin Soluble Solid Dispersion Immediate-Release Tablets for Prevention and Delay of the First Episode of Hepatic Encephalopathy: RED-C Phase 3 Study Design |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 4071 | Abstract Poster | Blood Metabolomics Predict 6-month Hospitalizations in a Multi-center Prospective North American Cohort of Outpatients with Cirrhosis |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 4061 | Abstract Poster | Hepatic Encephalopathy Defined Using Hospitalizations Significantly Adds to Risk Prediction for 90-day and 1-year Mortality above the MELD 3.0 and MELD-Na Scores in a National Cohort of Veterans |
| Jasmohan Bajaj | 8 a.m. - 5 p.m. | Hall C, 4192 | Abstract Poster | Patients With Cirrhosis and a History of Overt Hepatic Encephalopathy Experienced Lower 6-month All-Cause Mortality Rates with Rifaximin Monotherapy Versus Lactulose Monotherapy |
| S. Obi Aseem | 8 a.m. - 5 p.m. | Hall C, 4012 | Abstract Poster | Aramchol, A Stearoyl-CoA Desaturase Inhibitor, Attenuates the TGFβ-stimulated Fibroinflammatory Signals in Cholangiocyte Models of Primary Sclerosing Cholangitis |
| S. Obi Aseem | 8 a.m. - 5 p.m. | Hall C, 4385 | Abstract Poster | Spatial Transcriptomic Analysis of Historical Fixed Primary Sclerosing Cholangitis Livers Reveals Distinct Signaling Pathways |
| Sareh Bayatpour | 8 a.m. - 5 p.m. | Hall C, 4318 | Abstract Poster | Dysregulated Circular RNAs and Their Implications in the Pathogenesis of Primary Sclerosing Cholangitis |
| Vinay Jahagirdar | 8 a.m. - 5 p.m. | Hall C, 4385 | Abstract Poster | Increased Risk of Clostridiodes difficile Infection in Patients with Cirrhosis on Secondary Prophylaxis for Spontaneous Bacterial Peritonitis: A Retrospective Matched Cohort Study |
| J.P. Arab | 8 a.m. - 5 p.m. | Hall C, 5006 | Abstract Poster | Tapering Dose of Corticosteroid Is Safer and as Effective as A Fixed Dose of Corticosteroids in Patients with Severe Alcohol-Associated Hepatitis — A Multicenter Open-Label Randomized Controlled Trial (STASH Trial) |
| Arun Sanyal | 8 a.m. - 5 p.m. | Hall C, 5027 | Abstract Poster | Nis2+® Improves Secondary Risk Assessment for Referring Patients at Risk for or with Established MASLD to Specialists |
| Saul Karpen | 8 a.m. - 5 p.m. | Hall C, 5045 | Abstract Poster | Sustained, Long-Term Efficacy and Safety of Odevixibat in Patients with Progressive Familial Intrahepatic Cholestasis: Results from the Pedfic2 Phase 3, Open-Label Extension Study |
Tuesday, Nov. 19
| Name: | Time: | Location: | Type: | Title: |
|---|---|---|---|---|
| J.P. Arab | 9:30 - 9:50 a.m. | Hall A (livestream) | Presenter | TLM Debrief 2: Basic Science, Hepatitis, HCC, Cholestatic, MASLD, Alcohol-Associated Liver Disease and MetALD Debrief |
| Arun Sanyal | 10 -11:30 a.m. (presenting 10:40 - 10:50 a.m.) |
Hall C, 5019 | Abstract Poster | Impact of PNPLA3 RS738409 Variant on the Response to Tirzepatide Versus Placebo for the Treatment of Non-Cirrhotic MASH |
